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Neutralize the neutrophils! Neutrophil β1/β2
integrin activation contributes to
JAK2-V617F–driven thrombosis
Stephen T. Oh
Division of Hematology, Washington University School of Medicine, St. Louis, Missouri, USA.

Thrombosis is a major problem for patients with myeloproliferative
neoplasms (MPNs). Leukocytes have long been speculated to contribute
to thrombotic development in MPNs, but the exact role of these cells has
not been fully elucidated. In this issue of the JCI, Edelmann and colleagues
demonstrate that granulocytes from mice expressing an MPN-associated
JAK2 mutation (JAK2-V617F) exhibit enhanced adhesion to VCAM1- and
ICAM1-coated surfaces. The increased adhesion was shown to be mediated
by β1 (VLA-4) and β2 integrins, which are activated via inside-out signaling
induced by JAK2-V617F. In a murine thrombosis model, administration of
neutralizing antibodies targeting VLA-4 and β2 integrin reduced thrombosis,
suggesting the intriguing possibility that targeting these pathways could
have clinical relevance for MPN.

Thrombosis in myeloproliferative
neoplasms

Patients with myeloproliferative neoplasms
(MPNs) exhibit a propensity for thrombosis, which leads to significant morbidity and
mortality (1, 2). Both arterial (e.g., stroke,
myocardial infarction) and venous (e.g., pulmonary embolism, deep vein thrombosis)
systems can be affected, and unusual locations can be involved, such as the splanchnic
vasculature. The prevalence of thrombotic events has been reported to range from
10% to 29% in essential thrombocythemia
(ET) and 34% to 39% in polycythemia vera
(PV) patients (3). In one population-based
study, the incidence of arterial and venous
thrombosis in the first 3 months after MPN
diagnosis was 3 and 10 times higher, respectively, compared with the incidence in individuals without MPN (4).
Established risk factors for thrombosis in MPNs include older age and prior
history of thrombosis (5). As the defining

feature of PV is erythrocytosis, increased
RBC mass presumably is a primary factor that drives thrombosis. Thus, current
guidelines for PV patients recommend
maintaining the hematocrit (HCT) at a
level less than 45% (6). The importance
of this specific target was validated by a
study in which patients were randomized
to two different treatment goals (HCT
less than 45% versus HCT of 45%–50%)
that demonstrated that the lower HCT
goal associated with a lower likelihood of
death from cardiovascular causes or major
thrombotic events (7). In ET, the cardinal
feature is excessive platelet production,
although the degree of thrombocytosis
(i.e., platelet count) has not been shown to
correlate well with the risk of thrombosis
(2). Current guidelines indicate that ET
patients considered at high risk for thrombosis should be treated with cytoreductive
therapy (most commonly hydroxyurea) to
normalize platelet count (6).
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A role for leukocytes in
promoting MPN-associated
thrombosis?

MPN patients also commonly exhibit leukocytosis, and some studies have implicated leukocytosis as an independent risk factor for thrombosis (8–10). As noted above,
cytoreductive therapies, such as hydroxyurea, are commonly used to reduce the
HCT and/or platelet count in PV and ET
patients. However, it has been speculated
that an important benefit of hydroxyurea
may be to lower the white blood count
(WBC), thereby mitigating a potential contribution of leukocytes to thrombus formation (11). Neutrophils specifically have
been recently recognized as integral to
thrombus initiation and progression. Proposed mechanisms by which leukocytes
could contribute to thrombosis include the
release of proteolytic enzymes by activated neutrophils, as well as increased CD11b
expression, leading to stronger attachment of leukocytes to the endothelium
and platelets (1, 2). Abnormal generation
of neutrophil extracellular traps (NETs),
which contribute to coagulation and platelet aggregation, has also recently been
linked to the MPN-associated mutation
JAK2-V617F and thrombosis (12).

β1 and β2 integrin activation
contributes to JAK2-V617F–
mediated thrombosis

β1 and β2 integrins are essential mediators of leukocyte adhesion to the endothelium. In this issue, Edelmann and
colleagues hypothesized that in MPNs,
abnormal integrin function on leukocytes
could contribute to thrombus formation
(13). Granulocytes isolated from JAK2V617F knockin mice exhibited increased
adhesion to VCAM1 and ICAM1, ligands
for β1 and β2 integrin, respectively (Figure
1A). These findings are consistent with
recent studies from the same group show-
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granulocyte adhesion to VCAM1 was also
reduced following incubation with the
PI3K inhibitor wortmannin. Similar reductions in adhesion were obtained with the
Ca2+ and Mg2+ chelator BAPTA/AM, as well
as with knockdown of the Ca2+-dependent
enzyme CalDAG-GEFI, which is involved
in conversion of Rap1-GDP to Rap1-GTP.
Together, these findings suggest a role for
PI3K and CalDAG-GEFI signaling in Rap1
activation mediated by JAK2-V617F.
To determine the contribution of β1 and
β2 integrin activation to JAK2-V617F–induced
thrombosis Edelmann et al. utilized an inferior vena cava (IVC) ligation model. Compared
with JAK2-WT mice, JAK2-mutant mice
exhibited a significant increase in thrombus
size in response to partial IVC ligation that
was dramatically reduced by injection of β1
and β2 integrin–blocking antibodies (Figure 1A). These findings indicate that β1 and
β2 integrins play an important role in JAK2V617F–driven thrombosis, and suggest that
targeting β1 and β2 integrin activation could
potentially be efficacious clinically.

Perspective

Figure 1. The myeloproliferative neoplasm–associated mutation JAK2-V617 promotes thrombus
formation. (A) Neutrophils expressing JAK2-V617 have increased activation of β1 and β2 integrin,
resulting in increased adhesion to VCAM and ICAM1 on the vascular endothelium and enhanced
thrombus formation. JAK2-V617 enhances activation of Rap1, which then translocates to the plasma
membrane, thereby inducing the inside-outside signaling that shifts β integrins from a closed,
low-affinity confirmation to a high-affinity confirmation (inset). (B) Antibodies targeting β1 and β2
integrin reduce neutrophil adhesion, resulting in decreased thrombus formation.

ing that granulocytes from JAK2-mutant
MPN patients have increased adhesion to
VCAM1 (14).
Utilizing a conformation-specific antibody for β1 integrins, Edelmann and colleagues found that JAK2-V617F expression
shifts β1 integrins from a closed, low-affinity
confirmation to an open, high-affinity conformation (Figure 1A). This conformation
change occurred via integrin inside-outside signaling that involves Rap1-GTPase. In granulocytes from calreticulin-
mutant (CALR-mutant) MPN patients,
Rap1 was activated to a lesser degree than
in JAK2-V617F granulocytes. This differ-

ence in Rap1 expression is notable, since
CALR-mutant MPN patients are known to
be at lower risk for thrombosis compared
with JAK2-mutant MPN patients.
Activation of Rap1-GTP is associated
with translocation to the plasma membrane, and JAK2-V617F expression was
shown to promote Rap1 membrane relocalization. Moreover, GGTI-2147, a geranylgeranyltransferase inhibitor that blocks the
posttranslational modifications required
for Rap1 activation and translocation to
the plasma membrane, inhibited adhesion of JAK2-mutant (but not JAK2-WT)
granulocytes to VCAM1. JAK2-
mutant

Together, these studies by Edelmann and
colleagues highlight the role of neutrophils
in MPN-associated thrombosis and shed
light on the mechanism by which JAK2V617F activates β1and β2 integrins to promote thrombus formation. One outstanding question not addressed in this study
is whether inhibition of JAK2 with agents,
such as ruxolitinib, might impact β1 and β2
integrin activation driven by mutant JAK2.
Regardless, the studies shown establish that
blocking β1 and β2 integrin activation could
mitigate JAK2-V617F–driven thrombosis.
Agents that target various integrin subunits
have shown promising activity in several
inflammatory diseases, including multiple
sclerosis and inflammatory bowel disease,
although, integrin-targeting therapies have
been associated with increased susceptibility to infection (15, 16). Whether targeting
β1 and β2 integrin activation as a means of
preventing thrombosis in MPNs is a viable
strategy merits further exploration.
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